Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Baird analyst Ben Kallo downgraded the rating for Albemarle Corporation (NYSE:ALB) from Neutral to Underperform and maintained the price target of $60. Albemarle shares closed at $74.77 on Monday. See how other analysts view this stock.
- B of A Securities analyst Lorraine Hutchinson downgraded Tapestry, Inc. (NYSE:TPR) from Buy to Hold and raised the price target from $95 to $115. Tapestry shares closed at $110.42 on Monday. See how other analysts view this stock.
- Piper Sandler analyst Clarke Jeffries downgraded Cadence Design Systems, Inc. (NASDAQ:CDNS) from Overweight to Neutral and raised the price target from $328 to $355. Cadence Design shares closed at $333.76 on Monday. See how other analysts view this stock.
- HC Wainwright & Co. analyst Arthur He downgraded the rating for Adaptimmune Therapeutics plc (NASDAQ:ADAP) from Buy to Neutral. Adaptimmune Therapeutics shares closed at $0.1000 on Monday. See how other analysts view this stock.
- Scotiabank analyst Nicholas Yulico downgraded Healthpeak Properties, Inc. (NYSE:DOC) from Sector Outperform to Sector Perform and lowered the price target from $21 to $19. Healthpeak Properties shares closed at $17.26 on Monday. See how other analysts view this stock.
Considering buying ALB stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
